HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

pyripyropene A

from Aspergillus fumigatus FO-1289; structure given in first source

Also Known As:

FO 1289A

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - pyripyropene A: 4
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Terpenes: 1461
    - Sesquiterpenes: 1370
      - pyripyropene A: 4

Experts

1.	Ohshiro, Taichi: 3 articles (11/2015 - 05/2011)
2.	Tomoda, Hiroshi: 3 articles (11/2015 - 05/2011)
3.	Ishibashi, Shun: 2 articles (11/2015 - 05/2011)
4.	Matsuda, Daisuke: 2 articles (11/2015 - 05/2011)
5.	Rudel, Lawrence L: 2 articles (11/2015 - 05/2011)
6.	Yagyu, Hiroaki: 2 articles (11/2015 - 05/2011)
7.	Bayram, Ozgur: 1 article (12/2017)
8.	Brakhage, Axel A: 1 article (12/2017)
9.	Dolan, Stephen: 1 article (12/2017)
10.	Dos Reis, Thaila Fernanda: 1 article (12/2017)

Related Diseases

1.	Atherosclerosis 11/01/2015 - "New pyripyropene A derivatives, highly SOAT2-selective inhibitors, improve hypercholesterolemia and atherosclerosis in atherogenic mouse models." 02/01/2015 - "Of these, pyripyropene A derivatives, ACAT2-selective inhibitors, may be potential therapeutics for the treatment of atherosclerosis, homozygous familial hypercholesterolemia and nonalcoholic fatty liver disease." 05/01/2011 - "Pyripyropene A, an acyl-coenzyme A:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia."
2.	Hypercholesterolemia 11/01/2015 - "New pyripyropene A derivatives, highly SOAT2-selective inhibitors, improve hypercholesterolemia and atherosclerosis in atherogenic mouse models." 05/01/2011 - "Pyripyropene A, an acyl-coenzyme A:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia."
3.	Non-alcoholic Fatty Liver Disease 02/01/2015 - "Of these, pyripyropene A derivatives, ACAT2-selective inhibitors, may be potential therapeutics for the treatment of atherosclerosis, homozygous familial hypercholesterolemia and nonalcoholic fatty liver disease."
4.	Starvation 12/01/2017 - "Liquid chromatography-mass spectrometry under standard and iron starvation conditions confirmed that the ΔppzA mutant had reduced production of pyripyropene A, fumagillin, fumiquinazoline A, triacetyl-fusarinine C, and helvolic acid. "
5.	Hyperlipidemias (Hyperlipidemia) 05/01/2011 - "Pyripyropene A, an acyl-coenzyme A:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia."

Related Drugs and Biologics

1.	Iron
2.	Sterol O-Acyltransferase
3.	Acyl Coenzyme A (Acyl CoA)
4.	fumiquinazoline A
5.	fumagillin
6.	helvolic acid
7.	fusigen

Related Therapies and Procedures

1.	Therapeutics